BridgeBio Pharma (BBIO) Other Operating Expenses (2019 - 2026)

BridgeBio Pharma's Other Operating Expenses history runs 7 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 276.62% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $28.4 million (up 339.14% YoY), while the FY2025 annual figure was $21.0 million, up 440.54% from the prior year.
• Other Operating Expenses came in at $9.9 million for Q1 2026 at BridgeBio Pharma, up from $8.1 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $9.9 million in Q1 2026 to a low of $598000.0 in Q3 2023.
• A 5-year average of $2.6 million and a median of $1.1 million in 2024 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses slumped 58.28% in 2022 and surged 997.49% in 2025, its largest moves.
• BridgeBio Pharma's Other Operating Expenses stood at $647000.0 in 2022, then slipped by 7.57% to $598000.0 in 2023, then surged by 248.49% to $2.1 million in 2024, then soared by 289.01% to $8.1 million in 2025, then advanced by 22.6% to $9.9 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $9.9 million, $8.1 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison